Assembly Biosciences

IPO

Home - Assembly Bio

healthtech

biotech

Headquarters: South San Francisco, California
Employees: 51–200
Founded: 2012
Business Model: B2B
Website: assemblybio.com

Total Funding: $217.7M
Last Round: $175.0M Venture RoundAug 2025
Rounds: 3
Type: Public

About

Assembly Biosciences is a clinical-stage biotechnology company dedicated to developing innovative small-molecule antiviral therapeutics targeting serious viral diseases. The company's pipeline focuses on recurrent genital herpes, chronic hepatitis delta virus (HDV), and chronic hepatitis B (HBV). Assembly Bio partners with Gilead Sciences to advance novel antiviral treatments with the potential to change disease outcomes for patients worldwide.

LinkedIn X (Twitter)

Tech & App Stack

Tech & App Stack is available on paid plans

Upgrade to Silver or higher to reveal the full technology and app stack for any company.

View pricing

Sign up to view funding chart

Create a free account to see funding visualizations and detailed round data.

Create Free Account

Funding History

Venture Unknown

Assembly Biosciences

About

Tech & App Stack

Sign up to view funding chart

Funding History

Investors

Sign up to view investors

Similar Companies